KORU Medical’s CTO Buys 5,000 Shares in Quiet Confidence Move amid Volatile Stock }

Insider Buying at KORU Medical Systems Signals Confidence in a Volatile Stock

On May 18, 2026, Chief Technology Officer Eric Schiller executed a modest purchase of 5,000 shares of KORU Medical Systems at $3.91 each, raising his post‑transaction ownership to 5,000 shares. The deal came as the company’s share price hovered near its 52‑week low of $2.63, yet it was just above the current closing price of $3.96. Schiller’s action, while small in absolute terms, is consistent with a pattern of buying that has emerged over the past five months: he has accumulated more than 300,000 shares through option exercises and direct purchases, indicating a long‑term belief in the firm’s product pipeline and market positioning.

What This Means for Investors

For shareholders, Schiller’s purchase can be interpreted in two ways. First, insider buying often reflects confidence in a company’s future prospects; executives are typically well‑informed about upcoming developments such as new product approvals or regulatory milestones. Second, the transaction size is modest relative to the total outstanding shares, and the price is virtually identical to the market rate, suggesting that it is not a catalyst for a sharp price move. Investors should therefore view it as a quiet endorsement rather than a signal of imminent upside. The broader insider activity—most notably CEO Linda Tharby’s purchase of over 600,000 shares in a single trade—underscores a collective belief that the company’s valuation is poised for a rebound after a year‑long decline.

Schiller’s Historical Buying Patterns

Schiller’s history of equity transactions shows a steady accumulation of shares through both option grants and direct purchases. In early January, he exercised 232,297 options and bought 76,426 shares, adding a total of 308,723 shares to his portfolio. He has continued to buy shares on a quarterly basis, often at prices slightly below market, reflecting a strategy of “buy low, hold long.” Unlike some insiders who sell to diversify or for liquidity, Schiller has not disclosed any significant divestitures. His pattern of incremental purchases aligns with a patient‑capital approach that prioritizes company growth over short‑term portfolio adjustments.

Implications for KORU’s Future

KORU’s recent financials—particularly its negative price‑earnings ratio of –76.2 and a 47 % yearly gain—indicate that the stock is still undervalued relative to its earnings potential. The company’s focus on subcutaneous infusion devices for chronic conditions places it in a niche but growing market, where product approvals can create significant upside. Insider buying, especially from senior executives, may suggest that they foresee forthcoming regulatory milestones or commercial traction that could justify a higher valuation. However, the market’s recent 6 % monthly decline and the high volatility implied by the 52‑week high of $6.61 mean that any positive momentum will likely be gradual.

Takeaway for Financial Professionals

Executives’ buying activity, particularly from a technical leader like Schiller, offers a subtle yet meaningful barometer of internal confidence. While the trade itself is unlikely to move the stock dramatically, it complements a broader pattern of insider accumulation that may signal impending product or regulatory news. Analysts should monitor upcoming earnings releases and FDA submissions for KORU, and consider a moderate buy or hold recommendation for investors who are comfortable with the company’s valuation risk profile.